Published DateClear

Start Date

End Date

Category

• Pipeline3
• Research1

Organizations

• Bausch + Lomb70
• Eyes On Eyecare54
• Alcon, Inc.49
• American Optometric Association38
• Harrow32
• Glaukos30
• Topcon Healthcare26
• Regeneron25
• Aldeyra Therapeutics21
• Genentech19

Tags

• Geographic Atrophy4
• AMD3
• Clinical Trials3
• Gene Therapy3
• FDA2
• Injections2
• Retina2
• Wet Amd1

• Organizations: Complement Therapeutics✕

Clear all

Pipeline

Complement Therapeutics begins patient dosing in GA gene therapy trial

Opti-GAIN trial is evaluating a single subretinal injection of CTx-001, an AAV-based gene therapy modulating multiple pathways of the complement system.

Pipeline

Complement Therapeutics secures Fast Track Designation for lead GA therapy

AAV-based CTx001 modulates multiple pathways of the complement system when delivered as a one-time, subretinal injection.

Pipeline

Complement Therapeutics' GA gene therapy IND receives FDA clearance

Clearance gives green light to begin Q1 2026 patient enrollment for the Opti-GAIN study evaluating CTx001 as a one-time, durable treatment.

Research

First patient enrolled in study on GA secondary to AMD

The non-interventional i-GAIN study will track disease progression over 12 months.